Artemisinin-Based Combination Therapy Synergized with Medicinal Plants to Induce Musculotoxic Effects

Table 2

Effect of combination therapies on the mortality of myocyte (%).

Products	Days of incubation (D)	Mean ± SD
		0	1	2	3	4	5
MEM 2%	1.6	0.17	0.26	0.1	0.09	0.23	0.17 ± 0.08
ASAQ + PSA	1.6	12.89	40.33	59.76	54.20	58.68	45.17 ± 19.64
ASAQ + PEP	1.6	7.75	36.49	55.41	53.14	69.08	44.37 ± 23.52
AL + PSA	1.6	13.55	13.17	30.89	44.73	47.81	30.03 ± 16.50
AL + PEP	1.6	7.48	11.05	32.13	32.83	50.85	26.87 ± 17.78

ASAQ: artesunate/amodiaquine; AL: artemether/lumefantine; PSA: plant of Sida acuta; PEP: plant of Enantia polycarpa; SD = standard deviation. Statistical analyses were assessed using one-way analysis of variance (ANOVA) followed by Bonferroni’s posttest  < 0,05 versus control.